NIMGenetics
New Integrated Medical Genetics

GynTect®

INFORMED CONSENT

COD.
To be filled by the laboratory

Patient identification code:	
Name and surname:	**Date of birth:**
Reason for consultation:	
Full address with post code and city:	**ID:**
Patient e-mail:	**Telephone number:**
Name of Medical Practitioner:	**E-mail:**
Clinic/Hospital /Laboratory:	**Telephone Number:**

HPV Test: ☐ Positive ☐ Negative — **HPV genotypes:**

Baseline cytology:

☐ Normal ☐ ASCUS ☐ LSIL ☐ HSIL ☐ AGUS ☐ ASCH ☐ Capidermoid ☐ AIS
☐ Atypical glandular cells ☐ Adenocarcinoma

Basal colposcopy:

☐ Normal ☐ 1 Degree ☐ 2 Degree ☐ G1+G2 ☐ Suspected invasion ☐ Condyloma

Basal biospia of the cervix: ☐ **Yes** ☐ **No**

Exocervix result:

☐ Normal ☐ Squamous metaplasia ☐ CIN1/Condyloma ☐ CIN2-CIN3 ☐ Microinfiltrating epidermoid ca
☐ AdenoCa *in situ* ☐ Infiltrating AdenoCa ☐ Other tumors

Endocervix biospia:

☐ Normal ☐ Squamous metaplasia ☐ CIN1/Condiloma ☐ CIN2-CIN3 ☐ Microinfiltrating epidermoid ca
☐ AdenoCa *in situ* ☐ Infiltrating AdenoCa ☐ Other tumors

Cervical injury that motivates the request of GynTect® methylation test: ☐ CIN1 ☐ CIN2 ☐ CIN3 ☐ Others (specify): _____

1. I have received information on the indication, purpose, characteristics, scope and limitations of the **GynTect®** test for an adequate characterisation of the sample sent. I have also had the opportunity to read the information provided on the test through the information sheet attached to this document, and my questions have been answered satisfactorily.
2. I understand that **GynTect®** is a triage test, not a diagnostic test.
3. I understand that, despite the high sensitivity of the test, a normal result does not exclude the possibility of developing cervical intraepithelial neoplasia or cervical carcinoma.
4. I understand that, despite the high specificity, the presence of an altered methylation pattern does not imply the presence of cervical cancer.
5. I understand the limitations described in the attached information sheet and confirm that I have informed my physician of circumstances that may affect the reliability of the test, should any of them occur.
6. I declare that the personal and medical information I have provided is true and reliable.
7. I understand that I may be requested a new sample if the sample obtained is not optimal in terms of quality or quantity.
8. I understand and agree that the clinical team may contact me for additional clinical data.
9. I understand that the results of this test are not a substitute for a diagnosis made in a medical office, and it is recommended that these results be reported in a medical office. NIMGenetics, S.L. is not responsible for the use made by you or your physician of the results obtained, nor for any harmful consequences that may arise from the use of this information.

Therefore, I declare the aforementioned and consent to carry out the **GynTect® test.**

Signature Patient/Legal: _____ **Signature Medical Practitioner:** _____ **Date:** _____

GynTect2019V2:rev02:16/06/2021

NIMGenetics
New Integrated Medical Genetics

ADDITIONALLY,

- ☐ I consent to the use of my coded clinical data (i.e. without name or surname) and the results obtained for scientific publications, quality studies and databases in the healthcare field, while maintaining strict confidentiality about my identity. Coding implies that NIMGenetics will assign a code to your health data and test result that will replace your first and last name, so that your identity is not recognised.
- ☐ I consent to the transfer of my coded data (i.e. without name or surname) to third parties for its use in scientific research.
- ☐ I accept that NIMGenetics may contact **GynTect®** medical practitioner to request certain information after the study, which is detailed at the end of this document, in order to review the clinical evolution of the case and establish its relationship with the results offered by the **GynTect®** test.
- ☐ I authorise NIMGenetics, or its affiliates, to send me information related to its products and services.

Signature Patient/Legal: _____ **Date:** _____

General information about GynTect®: purpose and risks

The study we are requesting consent for is a triage test to detect, in the cells of the submitted sample, modifications in the genes (structures that contain the information about the cells' functions) associated with an increased risk of developing a tumour or cancer.

Cells contain genes (made up of DNA), whose alterations can lead to the appearance of cancers. It has also been known for years that, even if genes are 'fine', they can present reversible modifications that influence the way they work. These modifications of normal genes are called epigenetic changes.

One of these epigenetic changes is called *methylation*. Certain modifications in methylation increase the risk of cancer by altering the normal function of genes. These modifications are reversible and may change over time, so even if they are not present now, they may be present in the future.

GynTect® has proven high accuracy in identifying changes in methylation that occur in cells in the presence of cancer or high grade precancerous lesions (CIN3). The proposed study aims to evaluate the methylation status of specific DNA regions in the genes ASTN1, DLX1, ITGA4, RXFP3, SOX17 and ZNF671 applying the technology considered the best diagnostic strategy available today.

In case of positive results, there is a 66% probability of cervical cancer or high grade precancerous lesion (CIN3; cervical intraepithelial neoplasia grade 3). A negative result excludes the presence of precancerous lesions (CIN3) or cervical cancer with a 90% probability. Thus, the presence of such modifications does not imply a diagnosis, but it suggests a higher risk of presenting a precancerous lesion or cervical cancer. Therefore, your physician may indicate, based on the results of the different tests performed, the best option to complete the study and reach an accurate diagnosis.

This study is performed from a sample of cells from the cervix (obtained with a fine brush) as part of the diagnostic process. The sample will be taken during the gynaecological exam. The risks associated with the sampling process do not differ from those associated with the procedure used to perform the cytologies necessary for the early detection of precancerous lesions or cervical cancer. A new sample will be required if the sample obtained is not optimal in terms of quality or quantity.

The medical practitioner who requests/advises this test undertakes to provide information about the purpose of the analysis and provide counselling once the results have been obtained and evaluated. NIMGenetics is available to this professional to clarify any questions that may arise.

Place of analysis and destination of the biological sample

This test shall be carried out by technical personnel from Oncgnostics, a collaborating laboratory based in Germany, with whom NIMGenetics has signed a partnership agreement in compliance with the terms and the legal requirements demanded by current legislation.

GynTect2019V2;rev02;16/06/2021

If there is sufficient sample quantity left after the test, the surplus, and/or an aliquot of the DNA extracted, shall be coded and stored at the lab headquarters for a maximum period of 5 years, to be used in cases where a repeat study is necessary for diagnostic confirmation.

Only authorised personnel of NIMGenetics and the collaborating laboratory will have access to the data obtained from the processing of your sample (results of the genetic analyses).

Test results

Before testing, you should take into account the implications of the possible results.

- **Implications of a positive result (altered methylation pattern):**
  There have been cases of false positives, so if a result with an altered methylation pattern is obtained, the presence of cervical cancer or precancerous lesions should be confirmed by colposcopy and/or cervical biopsy.

- **Implications of a negative result (methylation pattern with no significant changes in relation to the control):**
  This result shall be evaluated in the context of the cervical cytology results and the assessment of HPV infection. This result excludes, with a 90% probability, the presence of a cancerous lesion. In the presence of cervical lesions it indicates a lower risk of tumour transformation. However, it does not exclude either the need for complementary tests and/or the revisions recommended by your physician.

- **Implications of a non-informative result:**
  In exceptional cases, it will not be possible to obtain a clear result.

The report of results will be sent to the requesting medical practitioner for explanation during consultation. The average period of availability of the report shall be 5 business days from the sample reception.

Test limitations

All genetic tests, regardless of the technique used for the specific case, have limitations that can affect the efficiency and reliability of the results obtained. Before requesting this study, the following aspects should be taken into consideration:

- This study does not determine the presence of genetic alterations (scope of the study).
- The methylation study is limited to six selected markers, so changes in methylation outside these regions will not be identified in this analysis.
- Sampling and sample shipping shall be done according to the specific recommendations for this study. Inadequate, scarce and/or poor quality samples may affect the efficiency and reliability of the results.
- The time that elapses from when a biological sample is collected to when it is processed can affect the integrity of the DNA.
- The presence of genetic alterations (such as deletions or duplications of the genes tested) or epigenetic disorders could alter the test result.

No genetic study technique is capable of identifying all the possible genetic or epigenetic alterations associated with any certain pathology, so each technology has its own specific instructions and limitations that will be reflected in the results report.

Data Protection and Confidentiality

Personal data and the genetic test results can only be accessed by duly authorised NIMGenetics technical and health personnel. This information will be confidential and shall be processed in accordance with the European Data Protection Regulation (Regulation (EU) 2016/679). The personal data that you provide us with, as well as those obtained from the analyses carried out, will be included and registered within the information processing systems of NIMGenetics for the diagnostic (and, if applicable, research) purpose described throughout this document.

NIMGenetics S.L. Parque Científico de Madrid. C/Faraday nº 7, Campus Cantoblanco. 28049 Madrid. CIF B-85332138

GynTect2019V2;rev02;16/06/2021

If you are not satisfied with the aforementioned processing, we will be unable to carry out the requested analysis. Likewise, we inform you that your personal information will not be disclosed to any person outside NIMGenetics, except for those who you authorise as requested in the following section "Further use of data", or as required by law. However, your personal information will not be used for any purpose other than that reported here, or that is incompatible with it.

In compliance with Law 14/2007, of 3 July, on Biomedical Research, this triage test result shall be stored for a period of 5 years after the analysis has been completed and, after such period has expired, it shall be anonymised if you have not exercised your right to cancel this genetic information.

You may exercise your rights of access, rectification, erasure, limitation of specific processing, portability and objection to the processing described at the following address: NIMGenetics GENÓMICA Y MEDICINA S.L.: Parque Científico de Madrid, C/ Faraday, 7 Campus Cantoblanco, 28049 Madrid. However, if you wish, you can also contact the Data Protection Officer at the following e-mail address: **dpo@nimgenetics.com**

For additional information on your personal data processing, please check the additional information on our website: **https://www.nimgenetics.com/politica-de-privacidad/**

Further use of the data

The results obtained may contribute to increasing the analytical capacity of the test and the current state of knowledge, providing benefits for new studies. NIMGenetics therefore requests your consent to use your coded clinical data (without your name and surname) and the results obtained for scientific publications, quality studies and databases in the healthcare field, maintaining strict confidentiality regarding your identity, which shall not be revealed under any circumstances.

Also, NIMGenetics requests your consent for the transfer of your codified data (without your name and surname) to third parties for its use in the field of scientific research.

NIMGenetics contact details

Feel free to contact NIMGenetics by calling +34 91 037 83 54 to clarify any doubts that may arise in connection with the content of this informed consent.

In order to perform the requested triage test, the informed consent document must be signed and dated.

Data to request after performing GynTect®

- **Follow-up time since GynTect® performance:** _____ months
- **Evolution since the initial injury**

  ☐ Progression to: _____ - Months since GynTect®: _____ months

  ☐ Persistence

  ☐ Regression to: _____ - Months since GynTect®: _____ months
- **Treatment performed**

  ☐ None ☐ Destructive ☐ Conization ☐ Others (specify): _____
- **Did the test result modified the terapeutic attitude?:**

  ☐ Yes ☐ No

GynTect2019V2;rev02:16/06/2021